213 related articles for article (PubMed ID: 19878763)
41. Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Das L; Gupta N; Dutta P; Walia R; Vaiphei K; Rai A; Radotra BD; Gupta K; Sreedharanunni S; Ahuja CK; Bhansali A; Tripathi M; Sood R; Dhandapani S
Front Endocrinol (Lausanne); 2021; 12():774686. PubMed ID: 34975752
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic implications of accurate classification of pituitary adenomas.
Mete O; Asa SL
Semin Diagn Pathol; 2013 Aug; 30(3):158-64. PubMed ID: 24144285
[TBL] [Abstract][Full Text] [Related]
43. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
44. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N; McCormack A
Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
[TBL] [Abstract][Full Text] [Related]
45. Aggressive Pituitary Adenomas and Carcinomas.
Ilie MD; Jouanneau E; Raverot G
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):505-515. PubMed ID: 32741485
[TBL] [Abstract][Full Text] [Related]
46. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature.
Lam G; Mehta V; Zada G
Neurosurg Focus; 2012 Jun; 32(6):E2. PubMed ID: 22655691
[TBL] [Abstract][Full Text] [Related]
47. Atypical, invasive, recurring Crooke cell adenoma of the pituitary.
Rotondo F; Cusimano M; Scheithauer BW; Coire C; Horvath E; Kovacs K
Hormones (Athens); 2012; 11(1):94-100. PubMed ID: 22450349
[TBL] [Abstract][Full Text] [Related]
48. Aggressive pituitary tumors (PitNETs).
Nishioka H
Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
[TBL] [Abstract][Full Text] [Related]
49. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.
Takeshita A; Inoshita N; Taguchi M; Okuda C; Fukuhara N; Oyama K; Ohashi K; Sano T; Takeuchi Y; Yamada S
Eur J Endocrinol; 2009 Oct; 161(4):553-9. PubMed ID: 19589911
[TBL] [Abstract][Full Text] [Related]
50. [Atypical pituitary tumors].
Krysiak R; Okopień B; Korzekwa M
Pol Merkur Lekarski; 2012 May; 32(191):323-8. PubMed ID: 22779341
[TBL] [Abstract][Full Text] [Related]
51. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
[TBL] [Abstract][Full Text] [Related]
52. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
53. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
54. Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review.
Cooper O; Bonert V; Liu NA; Mamelak AN
Front Endocrinol (Lausanne); 2021; 12():725014. PubMed ID: 34867776
[TBL] [Abstract][Full Text] [Related]
55. [Treatment of clinically nonfunctioning pituitary adenomas].
Alameda Hernando C; Lahera Vargas M; Varela Da Costa C
Endocrinol Nutr; 2010 Feb; 57(2):71-81. PubMed ID: 20227355
[TBL] [Abstract][Full Text] [Related]
56. Diagnosis & management of pituitary tumors.
Weinstein J; Isaacs S; Shore D; Blevins LS
Compr Ther; 1997 Sep; 23(9):594-604. PubMed ID: 9285160
[TBL] [Abstract][Full Text] [Related]
57. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.
Daly AF; Rixhon M; Adam C; Dempegioti A; Tichomirowa MA; Beckers A
J Clin Endocrinol Metab; 2006 Dec; 91(12):4769-75. PubMed ID: 16968795
[TBL] [Abstract][Full Text] [Related]
58. Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastases.
Shastri BR; Nanda A; Fowler M; Levine SN
World Neurosurg; 2013 Feb; 79(2):404.e11-6. PubMed ID: 22079280
[TBL] [Abstract][Full Text] [Related]
59. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours.
Acosta-Gómez MJ; Muros MA; Llamas-Elvira JM; Ramírez A; Ortega S; Sabatel G; Ramos C; de la Riva-Aguilar A
Br J Radiol; 2005 Feb; 78(926):110-5. PubMed ID: 15681321
[TBL] [Abstract][Full Text] [Related]
60. Clinical management of pituitary carcinomas.
Oh MC; Tihan T; Kunwar S; Blevins L; Aghi MK
Neurosurg Clin N Am; 2012 Oct; 23(4):595-606. PubMed ID: 23040746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
